Abstract

Drug delivery to the neonatal and premature pediatric populations is very challenging. This research assessed the potential of delivering midazolam by transdermal iontophoresis as an alternative strategy in pediatric therapy. In vitro experiments used intact and tape-stripped porcine skin as models for the skin barrier function of full-term and premature newborns, respectively. Midazolam transdermal transport was significantly enhanced by applying higher currents, increasing the formulation pH, and optimizing the drug’s mole fraction in the vehicle. When the skin barrier was decreased to half of its baseline competence, the passive permeation of midazolam increased by approximately 60-fold; and complete stratum corneum removal led to an additional 20-fold enhancement in permeation. Iontophoresis retained control of the drug transport trough partially compromised skin. However, a very high passive contribution undermined the iontophoretic control when the barrier was fully compromised. Overall, midazolam delivery could be rate-controlled by iontophoresis in most circumstances, and therapeutically useful fluxes could be achieved.
LanguageEnglish
Pages137-143
Number of pages7
JournalEuropean Journal of Pharmaceutical Sciences
Volume128
Early online date5 Dec 2018
DOIs
StatusPublished - 1 Feb 2019

Keywords

  • Iontophoresis
  • Midazolam
  • Passive diffusion
  • Pediatric drug delivery
  • Skin barrier function
  • Transdermal drug delivery

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Potential of iontophoresis as a drug delivery method for midazolam in pediatrics. / Djabri, Asma; Guy, Richard; Delgado-Charro, Maria.

In: European Journal of Pharmaceutical Sciences, Vol. 128, 01.02.2019, p. 137-143.

Research output: Contribution to journalArticle

@article{e2dacabbeeae4c6f9f60eaf8ef0eb8bd,
title = "Potential of iontophoresis as a drug delivery method for midazolam in pediatrics",
abstract = "Drug delivery to the neonatal and premature pediatric populations is very challenging. This research assessed the potential of delivering midazolam by transdermal iontophoresis as an alternative strategy in pediatric therapy. In vitro experiments used intact and tape-stripped porcine skin as models for the skin barrier function of full-term and premature newborns, respectively. Midazolam transdermal transport was significantly enhanced by applying higher currents, increasing the formulation pH, and optimizing the drug’s mole fraction in the vehicle. When the skin barrier was decreased to half of its baseline competence, the passive permeation of midazolam increased by approximately 60-fold; and complete stratum corneum removal led to an additional 20-fold enhancement in permeation. Iontophoresis retained control of the drug transport trough partially compromised skin. However, a very high passive contribution undermined the iontophoretic control when the barrier was fully compromised. Overall, midazolam delivery could be rate-controlled by iontophoresis in most circumstances, and therapeutically useful fluxes could be achieved.",
keywords = "Iontophoresis, Midazolam, Passive diffusion, Pediatric drug delivery, Skin barrier function, Transdermal drug delivery",
author = "Asma Djabri and Richard Guy and Maria Delgado-Charro",
year = "2019",
month = "2",
day = "1",
doi = "10.1016/j.ejps.2018.11.035",
language = "English",
volume = "128",
pages = "137--143",
journal = "European Journal of Pharmaceutical Sciences",
issn = "0928-0987",
publisher = "Elsevier",

}

TY - JOUR

T1 - Potential of iontophoresis as a drug delivery method for midazolam in pediatrics

AU - Djabri, Asma

AU - Guy, Richard

AU - Delgado-Charro, Maria

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Drug delivery to the neonatal and premature pediatric populations is very challenging. This research assessed the potential of delivering midazolam by transdermal iontophoresis as an alternative strategy in pediatric therapy. In vitro experiments used intact and tape-stripped porcine skin as models for the skin barrier function of full-term and premature newborns, respectively. Midazolam transdermal transport was significantly enhanced by applying higher currents, increasing the formulation pH, and optimizing the drug’s mole fraction in the vehicle. When the skin barrier was decreased to half of its baseline competence, the passive permeation of midazolam increased by approximately 60-fold; and complete stratum corneum removal led to an additional 20-fold enhancement in permeation. Iontophoresis retained control of the drug transport trough partially compromised skin. However, a very high passive contribution undermined the iontophoretic control when the barrier was fully compromised. Overall, midazolam delivery could be rate-controlled by iontophoresis in most circumstances, and therapeutically useful fluxes could be achieved.

AB - Drug delivery to the neonatal and premature pediatric populations is very challenging. This research assessed the potential of delivering midazolam by transdermal iontophoresis as an alternative strategy in pediatric therapy. In vitro experiments used intact and tape-stripped porcine skin as models for the skin barrier function of full-term and premature newborns, respectively. Midazolam transdermal transport was significantly enhanced by applying higher currents, increasing the formulation pH, and optimizing the drug’s mole fraction in the vehicle. When the skin barrier was decreased to half of its baseline competence, the passive permeation of midazolam increased by approximately 60-fold; and complete stratum corneum removal led to an additional 20-fold enhancement in permeation. Iontophoresis retained control of the drug transport trough partially compromised skin. However, a very high passive contribution undermined the iontophoretic control when the barrier was fully compromised. Overall, midazolam delivery could be rate-controlled by iontophoresis in most circumstances, and therapeutically useful fluxes could be achieved.

KW - Iontophoresis

KW - Midazolam

KW - Passive diffusion

KW - Pediatric drug delivery

KW - Skin barrier function

KW - Transdermal drug delivery

UR - http://www.scopus.com/inward/record.url?scp=85057577793&partnerID=8YFLogxK

U2 - 10.1016/j.ejps.2018.11.035

DO - 10.1016/j.ejps.2018.11.035

M3 - Article

VL - 128

SP - 137

EP - 143

JO - European Journal of Pharmaceutical Sciences

T2 - European Journal of Pharmaceutical Sciences

JF - European Journal of Pharmaceutical Sciences

SN - 0928-0987

ER -